BiotechTube

Artesunate-mefloquine + Atovaquone-proguanil + Artemether-lumefantrine

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Malaria

Conditions

Malaria, Falciparum

Trial Timeline

May 1, 2007 → Nov 1, 2008

NCT ID
NCT00444106

About Artesunate-mefloquine + Atovaquone-proguanil + Artemether-lumefantrine

Artesunate-mefloquine + Atovaquone-proguanil + Artemether-lumefantrine is a approved stage product being developed by Novartis for Malaria. The current trial status is completed. This product is registered under clinical trial identifier NCT00444106. Target conditions include Malaria, Falciparum.

What happened to similar drugs?

10 of 18 similar drugs in Malaria were approved

Approved (10) Terminated (1) Active (8)
✅COA566NovartisApproved
✅Co-artemetherNovartisApproved
✅Artemether-lumefantrineNovartisApproved
✅Flavoquine®, Camoquin® Suspension + Flavoquine®, Camoquin® SuspensionPfizerApproved
✅Coarsucam® (artésunate (AS) + amodiaquine (AQ) as fixed dose combination) + Coartem® (arthemether+ lumefantrine)SanofiApproved
✅Artesunate + Artesunate + Sulfadoxine-Pyrimethamine + arthemether + lumefantrineSanofiApproved
✅Artesunate + AmodiaquineSanofiApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00444106ApprovedCompleted

Competing Products

20 competing products in Malaria

See all competitors
ProductCompanyStageHype Score
SAR97276ASanofiPhase 2
27
SJ733 + CobicistatEisaiPhase 1
29
(+)-SJ000557733 (SJ733)EisaiPhase 2
35
E1018 + PlaceboEisaiPhase 1
36
ZY19489 + Ferroquine (FQ) + PlaceboZydus LifesciencesPhase 1
36
ZY19489 Capsule + Placebo CapsuleZydus LifesciencesPhase 1
29
M5717 330 mg + M5717 500 mg + M5717 660 mg + Pyronaridine 360 mg + Pyronaridine 360 mg + Pyronaridine 540 mg + Pyronaridine 720 mgMerckPhase 2
35
MK-7602 + Artemether/lumefantrine + Primaquine + Artesunate + Atovaquone/proguanilMerckPhase 1
29
M5717 60 mg + Pyronaridine + Atovaquone-Proguanil + M5717 200 mg + M5717 660mgMerckPhase 2
35
KLU156 + CoartemNovartisPhase 3
40
KAF156NovartisPhase 2
35
KAE609 + IV Artesunate + CoartemNovartisPhase 2
35
KAE609NovartisPhase 2
35
artemether:lumefantrine (2.5 mg:30 mg)NovartisPhase 2/3
30
Artemether-lumefantrine (COA566)NovartisPhase 2/3
38
INE963NovartisPhase 2
35
Ganaplacide + ItraconazoleNovartisPhase 1
29
KAE609 + Piperaquine PhosphateNovartisPhase 1
21
Artemether-lumefantrineNovartisPhase 3
40
KAE609 + SoC (Coartem) + KLU156NovartisPhase 2
35